The clinical trial of CoQ10 for saliva secresion or periodontal disease.

The clinical trial of CoQ10 for saliva secresion or periodontal disease. - The effect of CoQ10 on saliva secresion.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031939

Enrollment

100

Registered

2018-04-25

Start date

2006-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry mouth

Interventions

Dry mouth patients, placebo, 1month Healthy volunteer. placebo, 1month Dry mouth patients, ubiquinol, 100mg/day, 1month Healthy volunteer, ubiquinol, 100mg/day, 1month Dry mouth patients, ubiquinone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects underwent an evaluation of salivary secresion using the Saxon's test were divied into a dry mouth group (salivary secretion<2g/2min) and a healthy subjects group (salivary secretion 2>g/2min).

Exclusion criteria

Exclusion criteria: Patients who had a medical history of significant cardiovascular disease, significant pulmonary obstructive disease, gastrointestinal obstructive disease, epilepsy, or Parkinson's disease. Patients currently using drugs known to be xerostomic, taking disease-modifying anti-rheumatic drugs or predonisolone, undergoing radiotherapy for treatment of head and neck cancer.

Design outcomes

Primary

Measure	Time frame
saliva secretion, oxidative stress of blood or saliva, saliva CoQ10 determination, Inspection of periodontal tissues.	—

Countries

Japan

Contacts

Public ContactIchiro Saito

Tsurumi University School of Dental Medicine Department of Pathology

saito-i@tsurumi-u.ac.jp045-572-2888

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026